Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

By S. Loi, Stefan Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt and 6 more. Annals of Oncology, 2014

1,210 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/3ae92a0e2dd513fea27e9ee7aea09bb072209f74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Razelle Kurzrock
2. S. Patel

In Oncology

1. Razelle Kurzrock
2. S. Patel
3. H. Horlings

Citations in the corpus

• PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy (2015, background): “037), and expression profiling of these samples demonstrated that trastuzumab was associated with improved outcomes in the setting of upregulated CTLA-4 and PD-1 expression (33).”
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 (2015, neutral): “…highly proliferative breast cancers, and have been associated with increased pCR, longer disease-free survival (DFS), and improved overall survival (OS), independent of other prognostic factors [53, 54] in some studies, though not among patients treated with trastuzumab in the N9831 trial [55].”
• Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study (2019, neutral): “(%) [95% CI] 5 (24) [8-47] 10 (11) [5-19] 0 [0-17] 15 (16) [10-26]”
• Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2016, background): “TILs have been shown to have prognostic value in HER2-positive breast cancer and TN breast cancer.(45,46) Some evidence from subset analyses points to the ability of TILs to predict benefit from anthracycline-only therapy and from trastuzumab therapy in small cohorts of patients with HER2-positive d”